2012年1月27日,美国Amylin药厂宣布其研发的长效艾塞那肽缓释剂型Bydureon,只需一周注射一次,已经得到美国食品和药品管理局FDA的批准,用于临床。 BYDUREON 类药物: 活性成分(S): 指示(S): 药理作用: 临床试验: 共有252例患者进行了研究。与饮食和运动(19%),单一口服降糖剂(47%),或结合治疗口服降糖药(35%)患者接受治疗。平均基线糖化血红蛋白为8.4%。患者被随机分配接受一次七天(每周)或Byetta的(10mcg每日两次),除了现有的口服抗糖尿病药物Bydureon 2毫克。两次分配5mcg Byetta的发起治疗的患者每天再增加剂量10mcg 4周后,每日两次。 主要终点是从基线到24周(或提前终止时的最后一个值)的糖化血红蛋白的变化。 24周的治疗后,患者服用Bydureon经历了1.6个百分点,从基线糖化血红蛋白统计学优越减少,比服用Byetta的病人减少了0.9个百分点。两个治疗组达到统计学显着的减肥,研究结束的2.3千克Byetta的病人(减肥是次要终点)的Bydureon患者和1.4千克平均损失。 法律分类: 成人: 儿童: 禁忌症(S): 警告/注意事项: 互动(补): 不良反应(S):
最后更新: 欧洲批准Bydureon(exenatide缓释剂)用于2型糖尿病 欧盟已经批准 Bydureon每周注射一次的疗法上市,该药将在欧盟国家逐一推出。Bydureon是2型糖尿病治疗中首个也是唯一的每周注射一次疗法,在欧盟获批也是世界首次。 2011年7月5日欧盟已经批准 Bydureon(艾塞那肽2毫克粉剂和注射用缓释悬剂)上市,礼来公司将与 Amylin Pharmaceuticals 和 Alkermes 共同开发市场,在欧盟内的27个成员国逐一推出此药。 重要性: 胰高糖素样肽1受体激动剂 Bydureon? 是2型糖尿病治疗中首个也是唯一的每周注射一次疗法,在欧盟获批也是世界首次,只需要每周一次注射就可以很好地控制血糖。 适应症: 欧盟批准 Bydureon 与二甲双胍、磺脲类药物和噻唑烷二酮等单药或多药联合使用治疗2型糖尿病. BYDUREON Manufacturer:Amylin and Alkermes Pharmacological Class:Antidiabetic (glucagon-like peptide-1 [GLP-1] receptor agonist). Active Ingredient(s):Exenatide extended-release 2mg; pwd for SC inj after reconstitution. Indication(s):As adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes. Not for first-line therapy in patients inadequately controlled on diet and exercise. Pharmacology:Bydureon is an extended-release formulation of exenatide, a GLP-1 receptor agonist. Exenatide has been shown to bind and activate the human GLP-1 receptor in vitro. This leads to an increase in both glucose-dependent synthesis of insulin and in vivo secretion of insulin from pancreatic beta cells, by mechanisms involving cyclic AMP and/or other intracellular signaling pathways. Exenatide also moderates glucagon secretion and lowers glucagon concentrations during periods of hyperglycemia, slows gastric emptying, and decreases food intake. Clinical Trials:A 24-week, randomized, open-label trial was conducted to compare the safety and efficacy of Bydureon to Byetta in patients with type 2 diabetes and inadequate glycemic control with diet and exercise alone or with oral antidiabetic therapy, including metformin, a sulfonylurea, a thiazolidinedione, or combination of two of those therapies. A total of 252 patients were studied. Patients were treated with diet and exercise alone (19%), a single oral antidiabetic agent (47%), or combination therapy of oral antidiabetic agents (35%). The mean baseline HbA1c was 8.4%. Patients were randomly assigned to receive Bydureon 2mg once every seven days (weekly) or Byetta (10mcg twice-daily), in addition to existing oral anti-diabetic agents. Patients assigned to Byetta initiated treatment with 5mcg twice-daily then increased the dose to 10mcg twice-daily after 4 weeks. The primary endpoint was change in HbA1c from baseline to Week 24 (or the last value at time of early discontinuation). After 24 weeks of treatment, patients taking Bydureon experienced a statistically superior reduction in HbA1c of 1.6 percentage points from baseline, compared to a reduction of 0.9 percentage points for patients taking Byetta. Both treatment groups achieved statistically significant weight loss by the end of the study, with an average loss of 2.3kg for Bydureon patients and 1.4kg for Byetta patients (weight loss was a secondary endpoint). Legal Classification:Rx Adults:Give by SC inj in abdomen, thigh, or upper arm. Inject immediately after mixing. 2mg once every 7 days (weekly). Changing from Byetta: discontinue, then start Bydureon. Children:Not recommended. Contraindication(s):History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2. Warnings/Precautions:Not a substitute for insulin. Not for treating type 1 diabetes or diabetic ketoacidosis. Risk of thyroid C-cell tumors possible. History of pancreatitis; consider other antidiabetics. Monitor for pancreatitis; if suspected, promptly discontinue; if confirmed, do not restart. Severe GI disorders, renal impairment (CrCl <30mL/min), end-stage renal disease: not recommended. Renal transplantation. Pregnancy (Cat.C). Nursing mothers. Interaction(s):Concurrent insulin: not recommended. Increased risk of hypoglycemia with concomitant sulfonylurea, insulin, or other insulin secretagogues (eg, meglitinides); consider reducing dose of these. May delay absorption of oral drugs. Monitor warfarin. Adverse Reaction(s):GI upset, constipation, headache, inj site reactions; possible antibody formation (glycemic response may be attenuated), pancreatitis (may be fatal), hypersensitivity reactions. How Supplied:Single-dose trays—4 (each contains 1 vial, 1 prefilled syringe with diluent, vial connector and needles) Last Updated:2/24/2012 |
Bydureon(exenatide,艾塞那肽缓释剂)简介:
2012年1月27日,美国Amylin药厂宣布其研发的长效艾塞那肽缓释剂型Bydureon,只需一周注射一次,已经得到美国食品和药品管理局FDA的批准,用于临床。
BYDUREON制造商:Amylin和Alkermes公司
类药物:降 ... 责任编辑:admin |
最新文章更多推荐文章更多热点文章更多
|